- Home
- SMHI vs IPHA Comparison
SMHI vs IPHA Comparison
Compare SMHI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMHI | IPHA |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.2M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SMHI | IPHA |
|---|---|---|
| Price | $6.86 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 109.1K | 22.9K |
| Earning Date | 02-25-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $245,311,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.63 | $1.63 |
| 52 Week High | $7.88 | $2.63 |
Technical Indicators
Market Signals| Indicator | SMHI | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 51.09 |
| Support Level | $5.86 | $1.74 |
| Resistance Level | $6.40 | $1.85 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 95.87 | 62.50 |
Price Performance
Historical ComparisonAbout SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.